Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Biotechnology

Healthcare
$0.37 -6.21%

-$0.10 today

Market cap
$69.21M
Beta
2.76
P/E (TTM)
-1.2
EPS (TTM)
-$1.24
52W Low $0.72High $3.65

Volume 1.50M

Average 2.02M

NMRA Total Debt

Short-term and long-term borrowings combined.

Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 56.3% from a year ago

Total debt stood at $410K at the end of Q1 FY2026, down 56.3% from a year earlier and down 14.0% from the prior quarter. Over 3 fiscal years it compounded at -61.6% a year.

Context

  • Total debt amounted to 0.3% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Total debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -56.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$410K-14.0% QoQ
Last fiscal yearDec 2025
$477K-74.3% YoY
Year agoMar 2025
$938K-56.3% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-56.3%——
1 year-74.3%——
3-year CAGR-61.6%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
477K USD
Year-over-year change
-74.3%
4-year CAGR
-30.6%

Total Debt vs competitors

How NMRA compares with its peers on the latest reported figures

  • NMRA's Mar 2026 total debt of $410K is the lowest of the 10 companies compared; the peer median is $36.43M.
  • Its year-over-year change of -56.3% is the 8th highest of 10, against a peer median of -25.2%.
  • Total debt amounts to 0.3% of total assets for NMRA, versus a peer median of 6.5%.
NMRA Competitors Peer median
Total Debt for NMRA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OMEROmeros CorporationMar 2026$310.63M -25.2%-11.2%108.5%
ADCTADC Therapeutics S.A.Mar 2026$116.67M -74.1%+50.1%40.0%
AUTLAutolus Therapeutics plcMar 2026$79.96M -74.3%+143.8%15.2%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026$57.71M -45.7%+4.0%21.5%
ALMSAlumis Inc. Common StockJun 2026$36.43M -6.1%+174.8%6.5%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$20.54M -13.9%+9.9%4.0%
BCYCBicycle Therapeutics plcMar 2026$15.34M +68.2%-26.6%2.4%
PRTAProthena Corporation plcMar 2026$7.65M -25.0%+28.9%2.2%
FULCFulcrum Therapeutics, Inc.Mar 2026$5.87M -27.6%-21.7%1.7%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$410K -56.3%-61.6%0.3%
Peer median (excluding NMRA) $36.43M-25.2%+9.9%6.5%

Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents409.25M240.94M374.04M142.15M182.53M
Short-term Investments0130.94M79.94M165.43M0
Net Receivables200K919K939K00
Inventory00000
Other Current Assets125K50K06.48M8.01M
Total Current Assets415.6M387.96M478.28M314.06M190.54M
Property, Plant & Equipment (Net)4.04M10.64M6.86M2.92M457K
Goodwill00000
Intangible Assets00000
Long-term Investments023.51M9.85M00
Tax Assets00000
Other Non-current Assets9.65M4.13M1.21M053K
Total Non-current Assets13.69M38.28M17.92M2.92M510K
Total Assets429.3M426.23M496.2M316.97M191.05M
Account Payables1.64M7.15M337K3.31M3.38M
Short-term Debt0000284K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities8.13M10.04M10.15M10.11M28.79M
Total Current Liabilities23.28M23.7M25.11M29.89M32.45M
Long-term Debt0000193K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities730.24M844.32M155K22K54.53M
Total Non-current Liabilities731.24M849.39M2.01M22K54.73M
Total Liabilities754.52M873.08M27.12M29.91M87.18M
Common Stock3K3K16K16K17K
Retained Earnings(336.61M)(467.51M)(703.43M)(947.22M)(1.18B)
Accumulated OCI0(774K)(76K)62K0
Other Stockholders Equity00000
Minority Interest00000
Total Equity(325.22M)(446.85M)469.08M287.06M103.87M
Total Debt2.05M8.44M5.23M1.85M477K
Net Debt(407.2M)(232.5M)(368.81M)(140.3M)(182.05M)

Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.